Russian FederationTuberculosis profile
Population  2016 144 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 12 (11–12) 8.2 (7.8–8.6)
Mortality (HIV+TB only) 1.7 (0.85–2.7) 1.2 (0.59–1.9)
Incidence  (includes HIV+TB) 94 (61–135) 66 (42–94)
Incidence (HIV+TB only) 18 (12–26) 13 (8.1–18)
Incidence (MDR/RR-TB)** 63 (52–74) 44 (36–51)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 4.7 (2.9–6.6) 25 (15–35) 30 (18–42)
Males 5.4 (3.3–7.5) 59 (36–82) 65 (39–90)
Total 10 (6.1–14) 84 (51–118) 94 (61–135)
TB case notifications, 2016  
Total cases notified 121 046
Total new and relapse 92 407
          - % tested with rapid diagnostics at time of diagnosis 70%
          - % with known HIV status 87%
          - % pulmonary 91%
          - % bacteriologically confirmed among pulmonary 51%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 98% (68–150)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.15 (0.1–0.21)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 16 570 21%
          - on antiretroviral therapy 10 549 64%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  47 000
(46 000–47 000)
Estimated % of TB cases with MDR/RR-TB 27% (27–28) 65% (65–66)  
% notified tested for rifampicin resistance 40% 63% 57 910
MDR/RR-TB cases tested for resistance to second-line drugs    
Laboratory-confirmed cases MDR/RR-TB: 27 363, XDR-TB:
Patients started on treatment **** MDR/RR-TB: 25 713, XDR-TB: 1 772
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 71% 80 424
Previously treated cases, excluding relapse, registered in 2015 50% 8 294
HIV-positive TB cases registered in 2015 51% 694
MDR/RR-TB cases started on second-line treatment in 2014 51% 20 089
XDR-TB cases started on second-line treatment in 2014 31% 2 209
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment 93%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
100% (100–100)
TB financing, 2017  
National TB budget (US$ millions) 1 175
Funding source: 100% domestic, 0% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-12-17 Data: www.who.int/tb/data